TP53 and breast cancer: Here we used a highly specific, double Nutlin-3-based PROTAC to target mdm2 in native, p53 wildtype MCF-7 (here MCF-7nat), abemaciclib-resistant MCF-7 (MCF-7res), and p53-mutated T-47D BC cells.